Research progress on evodiamine, a bioactive alkaloid of Evodiae fructus: Focus on its anti‑cancer activity and bioavailability (Review)

  • Authors:
    • Chaodan Luo
    • Jingwen Ai
    • Erfang Ren
    • Jianqiang Li
    • Chunmei Feng
    • Xinrong Li
    • Xiaojie Luo
  • View Affiliations

  • Published online on: September 20, 2021     https://doi.org/10.3892/etm.2021.10762
  • Article Number: 1327
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Evodiae fructus (Wu‑Zhu‑Yu in Chinese) can be isolated from the dried, unripe fruits of Tetradium ruticarpum and is a well‑known traditional Chinese medicine that is applied extensively in China, Japan and Korea. Evodiae fructus has been traditionally used to treat headaches, abdominal pain and menorrhalgia. In addition, it is widely used as a dietary supplement to provide carboxylic acids, essential oils and flavonoids. Evodiamine (EVO) is one of the major bioactive components contained within Evodiae fructus and is considered to be a potential candidate anti‑cancer agent. EVO has been reported to exert anti‑cancer effects by inhibiting cell proliferation, invasion and metastasis, whilst inducing apoptosis in numerous types of cancer cells. However, EVO is susceptible to metabolism and may inhibit the activities of metabolizing enzymes, such as cytochrome P450. Clinical application of EVO in the treatment of cancers may prove difficult due to poor bioavailability and potential toxicity due to metabolism. Currently, novel drug carriers involving the use of solid dispersion techniques, phospholipids and nanocomplexes to deliver EVO to improve its bioavailability and mitigate side effects have been tested. The present review aims to summarize the reported anti‑cancer effects of EVO whilst discussing the pharmacokinetic behaviors, characteristics and effective delivery systems of EVO.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 22 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Luo C, Ai J, Ren E, Li J, Feng C, Li X and Luo X: Research progress on evodiamine, a bioactive alkaloid of <em>Evodiae fructus</em>: Focus on its anti‑cancer activity and bioavailability (Review). Exp Ther Med 22: 1327, 2021
APA
Luo, C., Ai, J., Ren, E., Li, J., Feng, C., Li, X., & Luo, X. (2021). Research progress on evodiamine, a bioactive alkaloid of <em>Evodiae fructus</em>: Focus on its anti‑cancer activity and bioavailability (Review). Experimental and Therapeutic Medicine, 22, 1327. https://doi.org/10.3892/etm.2021.10762
MLA
Luo, C., Ai, J., Ren, E., Li, J., Feng, C., Li, X., Luo, X."Research progress on evodiamine, a bioactive alkaloid of <em>Evodiae fructus</em>: Focus on its anti‑cancer activity and bioavailability (Review)". Experimental and Therapeutic Medicine 22.5 (2021): 1327.
Chicago
Luo, C., Ai, J., Ren, E., Li, J., Feng, C., Li, X., Luo, X."Research progress on evodiamine, a bioactive alkaloid of <em>Evodiae fructus</em>: Focus on its anti‑cancer activity and bioavailability (Review)". Experimental and Therapeutic Medicine 22, no. 5 (2021): 1327. https://doi.org/10.3892/etm.2021.10762